Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

A method of treating or ameliorating a gastrointestinal hypomotility disorder comprising administering to a subject in need of such treatment a composition consisting essentially of a therapeutically effective amount of a neurotrophin-3 receptor activating compound such that the disorder is treated or ameliorated, and wherein the disorder is caused by or associated with a pathological condition selected from the group consisting of obstipation, idiopathic abdominal distention, irritable bowel syndrome, megacolon associated with hypothyroidism, pseudo-obstruction of the gastrointestinal tract, hypomotility of the stomach and colon associated with diabetes mellitus, myopathic disorders, geriatric hypomotility disorders, jejunal-ileal bypass with secondary megacolon, hypomotility associated with cancer chemotherapy, hypomotility associated with severe burns, hypomotility associated with syndromes of depression, post-operative intestinal distension, and use of opiate pain killers.

A method of treating or ameliorating a gastrointestinal hypomotility disorder comprising administering to a subject in need of such treatment a composition consisting essentially of a therapeutically effective amount of a recombinant methionyl neurotrophin-3 such that the disorder is treated or ameliorated, and wherein the effective amount is in the range of 25-500 μg/kg body weight of said subject.

A method of treating or ameliorating a gastrointestinal hypomotility disorder comprising administering to a subject in need of such treatment a composition consisting essentially of a therapeutically effective amount of a neurotrophin-3 receptor activating compound such that the disorder is treated or ameliorated, and wherein the disorder is of unknown cause.

A method of treating or ameliorating a gastrointestinal hypomotility disorder comprising administering to a healthy subject in need of such treatment a composition consisting essentially of a therapeutically effective amount of a neurotrophin-3 receptor activating compound such that the disorder is treated or ameliorated.